Dupixent Lawsuit for T-Cell Lymphoma

Dupixent (dupilumab) is a biologic medication used to treat atopic dermatitis, asthma, and other inflammatory conditions. It works by targeting specific immune pathways involved in allergic inflammation. For many patients with moderate to severe eczema, Dupixent has provided relief where topical medications failed. As a result, it has become one of the most widely prescribed biologic drugs for skin and respiratory conditions.

But for a growing number of patients, the experience with Dupixent has been very different. Over the past several years, doctors and researchers have reported cases in which patients treated with Dupixent were later diagnosed with cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma that primarily affects the skin. These reports have led to increasing scrutiny of whether Dupixent can worsen, accelerate, or mask CTCL in certain patients.

Lawyers across the country are now reviewing Dupixent lawsuits on behalf of patients who developed CTCL, mycosis fungoides, or Sézary syndrome after receiving Dupixent injections.

Call us today at 800-553-8082 or contact us online.

What Is Cutaneous T-Cell Lymphoma?

Cutaneous T-cell lymphoma is a cancer of the immune system involving malignant T cells that migrate to the skin. In its early stages, CTCL often looks almost indistinguishable from eczema, psoriasis, or other chronic inflammatory skin conditions. It behaves like a wolf in sheep’s clothing, presenting as ordinary rashes, plaques, itching, or redness that flare up and fade away, giving the impression of a manageable skin disorder rather than a developing cancer.

That disguise is what makes CTCL so dangerous. The disease can hide in plain sight for years, with biopsies that come back inconclusive and symptoms that mimic benign skin problems. Like a slow-burning fire behind a wall, CTCL may continue progressing quietly until it finally reveals itself, often at a more advanced stage that is far harder to treat.

The most common forms of CTCL are mycosis fungoides and Sézary syndrome. Both are serious, life-altering conditions that often require lifelong treatment, and in advanced cases, they can be fatal.

How Dupixent Fits Into CTCL Allegations

The concern raised in Dupixent lymphoma lawsuits is not that Dupixent causes cancer in every user. Instead, plaintiffs allege that Dupixent can trigger, accelerate, or obscure CTCL in a subset of patients who were misdiagnosed with eczema or other inflammatory skin conditions.

In many reported cases, patients started Dupixent for presumed dermatitis and initially experienced some symptom improvement. That improvement reinforced the belief that the condition was inflammatory rather than malignant. Over time, however, the disease progressed, worsened, or failed to behave like typical eczema. Further testing later revealed CTCL.

Plaintiffs argue that by suppressing visible inflammation without addressing the underlying disease process, Dupixent may delay diagnosis of CTCL and allow the cancer to progress unchecked.

Why CTCL Gets Misdiagnosed as Eczema

One of the most troubling aspects of these cases is that early cutaneous T-cell lymphoma and atopic dermatitis can look nearly identical… even to experienced dermatologists.

Both conditions present with:

• Red, inflamed patches
• Itchy, scaly skin
• Lichenification (thickened, leathery texture)
• Fissuring and cracking
• Symptoms that flare and fade over time

This is why patients end up on Dupixent for years while an undetected cancer quietly progresses.

Early-stage mycosis fungoides, the most common form of CTCL, often appears as flat, scaly patches that respond partially to topical steroids, just like eczema. Biopsies can come back inconclusive. Patients and doctors alike assume they are dealing with stubborn dermatitis, not a developing malignancy.

So Dupixent suppresses the visible inflammation. The redness fades. The itching improves. To the patient and prescriber, this looks like the drug is working. But if the underlying condition is CTCL rather than eczema, Dupixent may simply be masking the cancer’s symptoms while the disease continues to advance beneath the surface.

By the time the true diagnosis is made — often after the cancer has progressed to a more advanced stage — treatment options are more limited and outcomes are worse.

Regeneron and Sanofi-Aventis knew about this diagnostic gray zone. The companies should have:

• Warned prescribers that CTCL can mimic atopic dermatitis
• Recommended ruling out lymphoma before initiating Dupixent in adult-onset or treatment-resistant cases
• Advised T-cell clonality testing or repeat biopsy when patients fail to respond as expected
• Included clear “stop and investigate” guidance when symptoms evolve atypically

None of this appears in the current Dupixent label.

What Dupixent Lawsuits Allege

Plaintiffs in Dupixent lymphoma lawsuits are making serious allegations against Regeneron and Sanofi-Aventis. These cases are built primarily on failure to warn claims, supported by growing scientific evidence. The gap between the evidence and the drugs warning you could drie two Mack trucks through.

The core allegations include:

• Dupixent caused, accelerated, or unmasked T-cell lymphoma, depending on the patient. We allege the drug triggered cutaneous T-cell lymphoma (CTCL) or peripheral T-cell lymphoma (PTCL) in patients who had no prior cancer diagnosis, or accelerated disease progression in patients whose early-stage lymphoma was misdiagnosed as eczema.
• The manufacturers knew or should have known about the risk. Case reports, adverse event data submitted to the FDA, and peer-reviewed studies have documented the association between Dupixent and CTCL. This evidence was available to the companies well before their injuries occurred.
• The U.S. label contains no warning about CTCL or PTCL. Despite mounting evidence, the current Dupixent prescribing information makes no mention of cutaneous T-cell lymphoma, peripheral T-cell lymphoma, mycosis fungoides, or Sézary syndrome. The word “lymphoma” incredibly does not appear in the warnings.
• Atopic dermatitis and early CTCL look nearly identical. Both conditions present with red, itchy, scaly patches that flare and fade. Without explicit guidance to rule out lymphoma before prescribing Dupixent — especially in adults with atypical or treatment-resistant dermatitis — doctors may unknowingly treat a developing cancer.
• No guidance was provided to rule out lymphoma before treatment. Plaintiffs allege the companies failed to advise prescribers to consider T-cell clonality testing or skin biopsy in patients with adult-onset, refractory, or atypical dermatitis presentations.
• Everyone knows that with cancer, the earlier the diagnosis, the better.  With Dupixent, continued treatment masked symptoms and delayed diagnosis. In many cases, patients experienced initial improvement on Dupixent — which sadly reinforced the eczema diagnosis. But suppressing visible inflammation without addressing the underlying malignancy allowed the cancer to progress unchecked, often to a more advanced and harder-to-treat stage.
• Patients would have made different choices with adequate warnings. Dupixent is prescribed for conditions that are uncomfortable but not life-threatening. If people had known about the lymphoma risk, they would have pursued additional testing, chosen alternative treatments, or never started the drug at all.

The bottom line is that Regeneron and Sanofi-Aventis prioritized sales of a $14 billion blockbuster drug over patient safety, and the result has been unnecessary human suffering and death.

Medical Evidence Being Cited in Dupixent CTCL Claims

Several studies and case series are frequently cited in connection with Dupixent lymphoma litigation. Observational database studies have reported higher rates of CTCL diagnoses among patients treated with dupilumab compared to similar patients who were not exposed to the drug.

Other reports include case series where patients treated with Dupixent for presumed eczema initially improved, then experienced disease progression consistent with CTCL. These patterns have been discussed in dermatology journals and conferences, particularly in patients with adult-onset or treatment-resistant dermatitis.

While no single study proves causation, plaintiffs argue that the collective evidence is strong enough that manufacturers should have provided clearer warnings and guidance to prescribers.

Are These Dupixent Lawsuits Class Actions?

Dupixent CTCL lawsuits are not class actions. Each patient’s case depends heavily on individual medical history, biopsy results, timing of Dupixent use, and disease progression. That said, if enough cases are filed, the litigation could eventually be consolidated in federal multidistrict litigation for pretrial proceedings.

For now, these cases are being evaluated and filed individually.

Who May Qualify for a Dupixent Lawsuit?

You may have a viable Dupixent lawsuit if:

• You were prescribed Dupixent for eczema, asthma, or another approved use

• You were later diagnosed with cutaneous T-cell lymphoma

• Your condition worsened, progressed, or was delayed while on Dupixent

• You were diagnosed with mycosis fungoides or Sézary syndrome

• Your medical records show prolonged treatment despite atypical symptoms

Not every Dupixent patient with CTCL will qualify, but many cases deserve careful review.

What Happens Next in Dupixent Litigation?

Dupixent lawsuits are still in the early stages. Most activity right now involves medical record review, pathology evaluation, and case screening. As more cases are filed, courts may consider consolidation, coordinated discovery, and expert proceedings.

Patients considering a claim should not wait. Statutes of limitations apply, and delays can make cases harder to prove.

Are Lawyers Demanding a Dupixent Recall?

Maybe there should be a Dupixent recall.  That question is above our pay grade. But these lawsuits are not a push to recall the product.  They are pushing to tell doctors and patients of the risks so they can make informed decisions.

So failure to warn is the spine of these cases. A manufacturer that knows or should know that a subset of patients with adult-onset or refractory dermatitis may actually harbor early CTCL has a duty to communicate that risk.  The practical content of the warning is straightforward. Before initiating treatment in adults with atypical clinical courses and biopsy-suspicious lesions, consider T-cell clonality. After initiation, if the disease evolves in a way that is not typical for eczema, at the very least, do not keep escalating dupilumab while you “see if it helps.” Stop and investigate. Nothing about those messages conflicts with approved labeling. Everything about them tracks the real-world cases now in the lit

Design defect is less obvious in a biologic case than in a mechanical device case, but it is not off the table. Plaintiffs’ lawyers can credibly argue that the risk mitigation design for dupilumab was defective because it did not build in guardrails for a known diagnostic gray zone.

In a world where early mycosis fungoides can masquerade as eczema for years, a “safe” design includes robust prescriber education, explicit biopsy prompts in adult-onset disease, and clear stop rules when the clinical course deviates from eczema norms. That is risk management by design, and its absence is actionable where it predictably leads to delayed diagnosis and worse outcomes.

Plaintiffs’ attorneys will flesh all of this out.  But this will still be a failure to warn claim at its core.

What Is the Status of the Dupixent Lawsuits?

Lawyers have only started advertising and investigating these cases over the last month, so we are still at the very beginning. Right now, this is intake and record-building, not active litigation.

Will this lead to a Dupixient class action? No, but it will likely lead to federal multidistrict litigation (MDL), which shares some components with a class action lawsuit, but allows victims to retain their individual claims.

What do we have to do to get there? First, you need individual Dupixent lawsuits filed in courts nationwide. Once enough are on the books, the Judicial Panel on Multidistrict Litigation can be asked to centralize them before a single judge. That is the point where you start to see case management orders, coordinated discovery, and a pathway toward bellwether trials.

So the posture today is early, much earlier than many victims probably want. If the first complaints are filed later in 2025 or 2026, MDL consolidation could follow within a year. From there, discovery and expert battles will take another year or two. That means realistic settlement pressure is several years away.

For patients living with a lymphoma diagnosis, that timeline is hard to hear. But history shows that once filings increase and the science is tested in court, these cases move faster than you might expect. The important takeaway is that Dupixent lawsuits are just starting to form. What happens now – medical records are collected, clients are identified, and experts are engaged – sets the stage for how strong the litigation will be when it gets underway.  What you do want to do is initiate your claim now to avoid statute of limitations problems or other challenges that can arise from delays.

Who Qualifies for a Dupixent Lawsuit?

Our attorneys are reviewing cases from patients who received Dupixent and were later diagnosed with T-cell lymphoma. If you or a family member fits this profile, you may have a viable claim.

You may qualify if:

• You were prescribed Dupixent for eczema, asthma, chronic rhinosinusitis, eosinophilic esophagitis, prurigo nodularis, COPD, or another approved condition
• You were later diagnosed with cutaneous T-cell lymphoma (CTCL)
• You were later diagnosed with peripheral T-cell lymphoma (PTCL)
• You were diagnosed with mycosis fungoides
• You were diagnosed with Sézary syndrome
• Your skin condition worsened, failed to improve, or evolved atypically while on Dupixent
• Your lymphoma diagnosis was delayed while you continued treatment
• You had adult-onset dermatitis that was later reclassified as lymphoma